News - Page 120 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma

PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma

Post published:February 23, 2022
Post category:Press Release

Read more about the article Filament Health and ATMA Journey Centers Announce Licensing Agreement

Filament Health and ATMA Journey Centers Announce Licensing Agreement

Post published:February 23, 2022
Post category:Press Release

Read more about the article World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I

World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I

Post published:February 22, 2022
Post category:Press Release

Read more about the article TRYP THERAPEUTICS INC. ANNOUNCES BOARD CHANGES AND CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

TRYP THERAPEUTICS INC. ANNOUNCES BOARD CHANGES AND CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Post published:February 22, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in Depression; Cybin Partners with Chopra Foundation

Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in Depression; Cybin Partners with Chopra Foundation

Post published:February 18, 2022
Post category:Psychedelic Bulletin

Read more about the article COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

Post published:February 17, 2022
Post category:Press Release

Read more about the article Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions

Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions

Post published:February 17, 2022
Post category:Press Release

Read more about the article Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Post published:February 17, 2022
Post category:Press Release

Read more about the article HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market

Post published:February 17, 2022
Post category:Press Release

Read more about the article Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study

Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study

Post published:February 16, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.